The non-genotoxic activator of the p53 pathway Nutlin-3 shifts the balance between E2F7 and E2F1 transcription factors in leukemic cells

Maria Grazia Di Iasio, Giorgio Zauli

Research output: Contribution to journalArticlepeer-review

Abstract

Summary: The effect of Nutlin-3, a small molecule inhibitor of the MDM2/p53 interaction, was investigated on the steady-state mRNA levels of the transcription factors E2F1 and E2F7 in a cohort of primary B-chronic lymphocytic leukemia (B-CLL) patient samples (n = 15) and normal peripheral blood mononuclear cells (PBMC). A 24-h treatment with Nutlin-3 significantly down-regulated E2F1 and promoted the concomitant up-regulation of E2F7 in both leukemic and normal cells. Our data suggest that the ability of Nutlin-3 to up-regulate E2F7 likely represents an important molecular determinant in the anti-proliferative activity of Nutlin-3.

Original languageEnglish
Pages (from-to)458-460
Number of pages3
JournalInvestigational New Drugs
Volume31
Issue number2
DOIs
Publication statusPublished - Apr 2013

Keywords

  • B-chronic lymphocytic leukemia
  • E2F1
  • E2F7
  • Nutlin-3

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Oncology

Fingerprint Dive into the research topics of 'The non-genotoxic activator of the p53 pathway Nutlin-3 shifts the balance between E2F7 and E2F1 transcription factors in leukemic cells'. Together they form a unique fingerprint.

Cite this